Diffuse Large B-Cell Lymphoma | Topics

 
FDA Approves Loncastuximab Tesirine in Patients with R/R Large B-Cell Lymphoma
April 23, 2021

Data from the phase 2 LOTIS-2 clinical trial supported the accelerated approval of loncastuximab tesirine for patients with relapsed or refractory large B-cell lymphoma.

Reid Merryman, MD, on Potential Clinical Designs with MRD-Guidance for Patients with DLBCL
January 25, 2021

Expert details the potential for a clinical trial using minimal residual disease to guide therapy for patients with DLBCL.

Reid Merryman, MD, on Pre- and Post-Transplant Data for Patients with DLBCL
January 23, 2021

Merryman explains the value of evaluating separate transplant-related questions for patients with relapsed or refractory diffuse large B-cell lymphoma.